Cell line · CVCL_8792
Papers75
1 to 20 of 75
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Unc-51 like kinase 3 (ULK3) contributes to autophagy and cell survival in multiple myeloma. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| APRIL-driven BCMA/TACI dual-targeted ligand-drug conjugates for selective and potent therapy of multiple myeloma. | Acta Pharm Sin B | 2026 | Its Methods give the RRID and name the line | PubMed | |
| TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma. | iScience | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Schlafen 11 Is Overexpressed in Multiple Myeloma and Undergoes Nucleolar Translocation in Response to Bortezomib. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of Fibroblast Growth Factor Receptor 3 Signaling by Ponatinib Reduces Growth and Cytokine Production of Multiple Myeloma Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Base Editing of TIGIT Reprograms CD155 Signaling in Natural Killer Cells to Enhance Cancer Immunotherapy Efficacy. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Obesity Accelerates Multiple Myeloma Progression in Certain Mouse Models and in Humans. | Cancer Prev Res (Phila) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting BCMA in multiple myeloma with a trifunctional NK cell engager. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Anti-myeloma activity of the CXCR4 antagonist WZ811. | J Mol Med (Berl) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting PRKCN, an Essential Driver Orchestrating mTOR-IRF4 Axis Independently of Kinase Activity, in Multiple Myeloma. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FAPα+ Macrophages Orchestrate Immune Evasion in Multiple Myeloma by Dual Regulation of PD-L1 and T Cell Senescence. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Synergistic Treatment of Prostate Cancer and Multiple Myeloma using CD46-Targeted Radioimmunotherapy Antibody-Drug Conjugates. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| CD70-Targeting CAR NK Cells Overcome BCMA Downregulation and Improve Survival in High-risk Multiple Myeloma Models. | Blood Cancer Discov | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Darunavir analog precursors target mitochondrial metabolism in multiple myeloma and CLL. | Cancer Cell Int | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Divergent on-target off-tumor effects by CAR T and CAR NK cells suggest different efficacy and safety of cell therapies. | Oncoimmunology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| In-cell proximity target validation methods for heterobifunctional molecules with CRBN- or VHL-binder using AirID. | Commun Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dual targeting of BCMA and SLAMF7 with the CARtein system: chimeric antigen receptors with intein-mediated splicing elicit specific T cell activation against multiple myeloma. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma. | Adv Healthc Mater | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Exploring the role of cyclin D1 in the pathogenesis of multiple myeloma beyond cell cycle regulation. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Enitociclib, a selective CDK9 inhibitor: in vitro and in vivo preclinical studies in multiple myeloma. | Blood Neoplasia | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_8792/papers